Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SR123781A in ACS patients undergoing PCI (SHINE)
NCT00123565Phase 2Completed
- Sponsor
- Sanofi
- Start
- Dec 2004
- Primary completion
- May 2007
- Modality
- Allosteric Modulators
- Countries
- 18
01
Overview
Phase 2, randomised, double-blind trial of sr-123781a in acute coronary syndrome (ACS), unstable angina and non-ST segment elevation myocardial infarction (NSTEMI) (3 arms), sponsored by Sanofi. Primary endpoint: Composite of all causes of death, new myocardial infarction, or severe myocardial ischemia requiring urgent repeat target vessel revascularization at 7 days. Started Dec 2004; status: completed.
02
Drugs
sr-123781a
03
Conditions
acute coronary syndrome (ACS)unstable anginanon-ST segment elevation myocardial infarction (NSTEMI)
Beyond the preview
Go deeper on NCT00123565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00123565.